The Science of CJC-1295 Peptide: What Research Shows

What Is the CJC-1295 Peptide?

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) consisting of 30 amino acids. It binds GHRH receptors in the anterior pituitary to stimulate growth-hormone secretion. The DAC (Drug Affinity Complex) variant extends plasma half-life from roughly 30 minutes to 6-8 days by covalently bonding to circulating albumin.

CJC-1295 was first described in the early 2000s as a modified GHRH fragment. The native GHRH peptide is cleaved rapidly by dipeptidylpeptidase IV (DPP-IV), limiting its research utility in longer-duration studies. CJC-1295 addresses this by substituting four amino acids that confer DPP-IV resistance.

The most studied form is CJC-1295 with DAC. DAC stands for Drug Affinity Complex, a maleimidoproprionic acid (MPA) group attached to lysine at position 28. This group reacts with the free cysteine-34 residue on serum albumin, creating a covalent bond that dramatically extends the peptide's half-life in research models.

How CJC-1295 Interacts With Growth-Hormone-Releasing Pathways

The anterior pituitary contains somatotroph cells that express GHRH receptors on their surface. When CJC-1295 occupies these receptors, it activates adenylyl cyclase, raises intracellular cyclic AMP (cAMP), and triggers a downstream signalling cascade that promotes both GH synthesis and pulsatile GH release.

CJC-1295 With DAC vs. Without DAC: Key Research Differences

Choosing between the DAC and non-DAC forms is one of the first decisions researchers face when designing a CJC-1295 study. The choice shapes nearly every procedural variable.

CJC-1295 without DAC (Modified GRF 1-29)

• Half-life: approximately 30 minutes
• GH peak: sharp, within 15-30 minutes of administration in rodent models
• Suitable for: acute GH-pulse studies, circadian GH rhythm research, short-duration protocols

CJC-1295 with DAC

• Half-life: approximately 6-8 days (albumin-bound)
• GH peak: broader, sustained elevation over 1-4 days in animal models
• Suitable for: pharmacokinetic studies, chronic-exposure models, IGF-1 trajectory research

One practical point: because the DAC form circulates for nearly a week, any unexpected biological response in the animal model will also persist longer. Researchers designing safety-observation windows should factor this into their protocols.

Purity and identity verification matter here too. A DAC-bearing peptide that has undergone even partial hydrolysis at the maleimide linkage loses its albumin-binding capacity and begins to behave more like the non-DAC form. This is one reason mass spectrometry confirmation of intact molecular weight is essential before any study begins.

What Laboratory Studies Record About CJC-1295 Effects and Safety Signals

Laboratory research on cjc-1295 peptide benefits and safety signals comes primarily from rodent and non-human primate models. Human pharmacokinetic data does exist from a 2006 clinical pharmacology study in healthy adults (Teichman et al., Journal of Clinical Endocrinology and Metabolism), though that research was exploratory in nature.

In animal models, documented cjc-1295 side effects cluster into three categories:

1. Fluid retention markers, consistent with GH's known anti-natriuretic effects.

Researchers should note that cjc-1295 peptide benefits observed in animal models (improved body composition, enhanced tissue repair signalling) cannot be extrapolated to humans without formal clinical trial evidence. This compound is intended exclusively for laboratory research purposes and is not approved for therapeutic use.

For accurate interpretation of these signals in your own studies, correlating GH and IGF-1 assay results with batch-specific COA data is essential. Impure or partially degraded peptide will produce attenuated or erratic responses that compromise reproducibility.

Quality Standards That Matter for CJC-1295 Research Compounds

The integrity of any CJC-1295 study depends heavily on compound quality. Peptides degrade through hydrolysis, oxidation, and aggregation. Without verified purity data, you cannot distinguish a biological null result from a bad-batch artefact.

HPLC purity should be stated as a percentage with the method described (reverse-phase C18 column is standard). For research-grade CJC-1295, 98% purity or above is the accepted threshold. Any COA reporting only a single UV-absorption peak without retention-time data should raise a question.

Mass spectrometry (MS) confirms molecular identity. The expected molecular weight of CJC-1295 with DAC is approximately 3647 Da. If the MS trace is absent from the COA or shows a significant offset, the batch should not enter your study.

Batch and lot numbers allow you to trace results back to a specific manufacturing run. Studies using multiple batches should document each lot separately to account for inter-batch variability.

Storage and shipping conditions matter as much as manufacturing quality. CJC-1295 in lyophilized form is stable at -20 degrees C for 24 months when stored dry. Exposure to ambient humidity or freeze-thaw cycles degrades the structure. Verify that vendors ship on dry ice and provide temperature-monitoring documentation.

• Species selection: rat pituitary GHRH receptor expression patterns differ from mouse; review the species-specific literature before finalising your model.

For a complete breakdown of how CJC-1295 fits into the broader research peptide landscape, the full CJC-1295 research guide on PeptideValidation.com covers synthesis, mechanism, and vendor-qualification criteria in depth.

Is CJC-1295 a Steroid? Clearing Up the Classification

CJC-1295 is not a steroid. It is a synthetic peptide, meaning it is a chain of amino acids, not a lipid-derived molecule. Steroids are built on a four-ring carbon backbone derived from cholesterol. CJC-1295 works through a completely different receptor class (GHRH receptors) and has no androgenic, estrogenic, or glucocorticoid activity.

The question 'is cjc-1295 a steroid' appears regularly in researcher forums, and it is worth answering clearly.

Steroids are a class of lipid molecules defined by a cyclopentanoperhydrophenanthrene ring structure. Testosterone, cortisol, and estradiol are steroids. They act primarily through intracellular nuclear receptors to alter gene transcription over hours to days.

CJC-1295 is a peptide: a string of 30 amino acids held together by peptide bonds. It acts on a cell-surface G-protein-coupled receptor (the GHRH receptor), triggering cAMP signalling over a timescale of minutes. There is no structural, pharmacological, or mechanistic overlap with steroidal compounds.

This distinction matters practically. Peptides and steroids require different storage conditions, different analytical testing methods, and fall under different regulatory frameworks in research settings. A COA for a peptide will report purity by HPLC and identity by MS. A steroid panel on that same COA would be irrelevant and should not be interpreted as a quality indicator for CJC-1295.

It also matters for study design. Unlike anabolic steroids, CJC-1295 does not bind androgen receptors. Body-composition changes observed in animal models attributed to CJC-1295 operate through the GH/IGF-1 axis, not through androgen-driven anabolic pathways. Distinguishing these mechanisms is critical for accurate reporting and for designing the right control conditions in your experiment.

Frequently asked questions

What is the CJC-1295 peptide and what is it used for in research?

CJC-1295 is a synthetic 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH). In laboratory research, it is used to study growth-hormone secretion, IGF-1 signalling, and downstream metabolic and body-composition effects in animal models. It is not approved for human or veterinary therapeutic use.

What is the difference between CJC-1295 with DAC and without DAC?

The DAC (Drug Affinity Complex) modification extends the peptide's half-life from roughly 30 minutes to 6-8 days by binding to serum albumin. Without DAC, the molecule clears quickly and suits acute GH-pulse studies. With DAC, sustained GH and IGF-1 elevations make it suitable for pharmacokinetic and chronic-exposure study designs.

Is CJC-1295 a steroid?

No. CJC-1295 is a peptide built from amino acids, not a lipid-derived steroid molecule. It acts on GHRH receptors at the cell surface and has no androgenic, estrogenic, or glucocorticoid activity. Steroids and peptides differ in structure, mechanism of action, storage requirements, and analytical testing methods.

What purity level should research-grade CJC-1295 meet?

Research-grade CJC-1295 should show purity of 98% or above by HPLC, with molecular weight confirmed by mass spectrometry (approximately 3647 Da for the DAC form). A valid COA should include batch and lot numbers, test dates, and storage conditions. Batches without full analytical documentation should not be used in controlled studies.

Related in this series

• The Science of CJC-1295 Peptide: What Research Shows